Lung cancer immunotherapy duration study halted early

NCT ID NCT04880382

Terminated Knowledge-focused Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how long to continue immunotherapy in people with advanced non-small cell lung cancer who had already responded well to treatment for 6 to 12 months. The goal was to see if stopping or continuing treatment made a difference in keeping the cancer from growing. Only 8 people took part before the study was stopped early, so the results are very limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Centre Hospitalier de la Côte Basque

Bayonne, 64109, France
Clinique Marzet

Pau, France
Clinique Tivoli Ducos

Bordeaux, 33000, France
Institut Bergonie

Bordeaux, 33076, France
Polyclinique Bordeaux Nord Aquitaine

Bordeaux, 33077, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.